Literature DB >> 23148757

Plasmacytoid dendritic cells and immunotherapy in multiple sclerosis.

Felipe von Glehn1, Leonilda M Santos, Konstantin E Balashov.   

Abstract

Plasmacytoid dendritic cells (pDCs) are specialized APCs implicated in the pathogenesis of many human diseases. Compared with other peripheral blood mononuclear cells, pDCs express a high level of TLR9, which recognizes viral DNA at the initial phase of viral infection. Upon stimulation, these cells produce large amounts of type I interferon and other proinflammatory cytokines and are able to prime T lymphocytes. Thus, pDCs regulate innate and adaptive immune responses. This article reviews select aspects of pDC biology relevant to the disease pathogenesis and immunotherapy in multiple sclerosis. Many unresolved questions remain in this area, promising important future discoveries in pDC research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23148757      PMCID: PMC3556815          DOI: 10.2217/imt.12.117

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  105 in total

1.  [Karyometric research on lymph node cells in man. I. Germinoblasts, lymphoblasts & lymphocytes].

Authors:  K LENNERT; W REMMELE
Journal:  Acta Haematol       Date:  1958-02       Impact factor: 2.195

2.  Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta.

Authors:  Tarik Touil; Denise Fitzgerald; Guang-Xian Zhang; Abdolmohamad Rostami; Bruno Gran
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

3.  HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells.

Authors:  Elena Martinelli; Claudia Cicala; Donald Van Ryk; Diana J Goode; Katilyn Macleod; James Arthos; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

Review 4.  Environmental risk factors for multiple sclerosis. Part I: the role of infection.

Authors:  Alberto Ascherio; Kassandra L Munger
Journal:  Ann Neurol       Date:  2007-04       Impact factor: 10.422

5.  Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo.

Authors:  Shalin H Naik; Priyanka Sathe; Hae-Young Park; Donald Metcalf; Anna I Proietto; Aleksander Dakic; Sebastian Carotta; Meredith O'Keeffe; Melanie Bahlo; Anthony Papenfuss; Jong-Young Kwak; Li Wu; Ken Shortman
Journal:  Nat Immunol       Date:  2007-10-07       Impact factor: 25.606

6.  Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow.

Authors:  Nobuyuki Onai; Aya Obata-Onai; Michael A Schmid; Toshiaki Ohteki; David Jarrossay; Markus G Manz
Journal:  Nat Immunol       Date:  2007-10-07       Impact factor: 25.606

7.  Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a.

Authors:  Ralf Gutzmer; Brigitta Köther; Jörg Zwirner; Dorothea Dijkstra; Rahul Purwar; Miriam Wittmann; Thomas Werfel
Journal:  J Invest Dermatol       Date:  2006-06-15       Impact factor: 8.551

8.  Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.

Authors:  Roberto Lande; Josh Gregorio; Valeria Facchinetti; Bithi Chatterjee; Yi-Hong Wang; Bernhard Homey; Wei Cao; Yui-Hsi Wang; Bing Su; Frank O Nestle; Tomasz Zal; Ira Mellman; Jens-Michael Schröder; Yong-Jun Liu; Michel Gilliet
Journal:  Nature       Date:  2007-09-16       Impact factor: 49.962

9.  Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells.

Authors:  Anna K Manlapat; David J Kahler; Phillip R Chandler; David H Munn; Andrew L Mellor
Journal:  Eur J Immunol       Date:  2007-04       Impact factor: 5.532

10.  Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand.

Authors:  Tomoki Ito; Maria Yang; Yui-Hsi Wang; Roberto Lande; Josh Gregorio; Olivia A Perng; Xiao-Feng Qin; Yong-Jun Liu; Michel Gilliet
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

View more
  10 in total

1.  Resident plasmacytoid dendritic cells patrol vessels in the naïve limbus and conjunctiva.

Authors:  Arsia Jamali; Deshea L Harris; Tomas Blanco; Maria J Lopez; Pedram Hamrah
Journal:  Ocul Surf       Date:  2020-02-25       Impact factor: 5.033

2.  S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification.

Authors:  John R Teijaro; Sean Studer; Nora Leaf; William B Kiosses; Nhan Nguyen; Kosuke Matsuki; Hideo Negishi; Tadatsugu Taniguchi; Michael B A Oldstone; Hugh Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

Review 3.  Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation.

Authors:  Dimitry A Chistiakov; Alexander N Orekhov; Igor A Sobenin; Yuri V Bobryshev
Journal:  Front Physiol       Date:  2014-07-25       Impact factor: 4.566

4.  Divergent Immunomodulation Capacity of Individual Myelin Peptides-Components of Liposomal Therapeutic against Multiple Sclerosis.

Authors:  Vilena V Ivanova; Svetlana F Khaiboullina; Marina O Gomzikova; Ekaterina V Martynova; André M Ferreira; Ekaterina E Garanina; Damir I Sakhapov; Yakov A Lomakin; Timur I Khaibullin; Evgenii V Granatov; Farit A Khabirov; Albert A Rizvanov; Alexander Gabibov; Alexey Belogurov
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

Review 5.  Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications.

Authors:  Yun Cheng; Li Sun; Zhongxiang Xie; Xueli Fan; Qingqing Cao; Jinming Han; Jie Zhu; Tao Jin
Journal:  J Neurosci Res       Date:  2017-01-13       Impact factor: 4.164

Review 6.  Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.

Authors:  Ling Bai; Wei Chen; Jingtao Chen; Wei Li; Lei Zhou; Chao Niu; Wei Han; Jiuwei Cui
Journal:  J Transl Med       Date:  2017-02-27       Impact factor: 5.531

7.  CpG Type A Induction of an Early Protective Environment in Experimental Multiple Sclerosis.

Authors:  James Crooks; Marco Gargaro; Carmine Vacca; Claudia Volpi; Matteo Pirro; Giulia Scalisi; Antonella Turco; Rita Romani; Davide Matino; Abdolmohamad Rostami; Paolo Puccetti; Bruno Gran; Francesca Fallarino
Journal:  Mediators Inflamm       Date:  2017-03-05       Impact factor: 4.711

Review 8.  Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.

Authors:  Jorge Zorzopulos; Steven M Opal; Andrés Hernando-Insúa; Juan M Rodriguez; Fernanda Elías; Juan Fló; Ricardo A López; Norma A Chasseing; Victoria A Lux-Lantos; Maria F Coronel; Raul Franco; Alejandro D Montaner; David L Horn
Journal:  World J Stem Cells       Date:  2017-03-26       Impact factor: 5.326

Review 9.  Disease-Associated Plasmacytoid Dendritic Cells.

Authors:  Shuang Li; Jing Wu; Shan Zhu; Yong-Jun Liu; Jingtao Chen
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

10.  pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation.

Authors:  Fernanda V Duraes; Carla Lippens; Karin Steinbach; Juan Dubrot; Dale Brighouse; Nathalie Bendriss-Vermare; Shohreh Issazadeh-Navikas; Doron Merkler; Stephanie Hugues
Journal:  J Autoimmun       Date:  2015-09-01       Impact factor: 7.094

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.